Motivational Interviewing to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse - 1 - Full Text View

Sponsor:	Yale University
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00032994

Purpose

The purpose of this study is to assess Motivational Interviewing (MI) to improve treatment engagement and outcome in subjects seeking treatment for substance abuse.

Condition	Intervention	Phase
Substance-Related Disorders	Behavioral: Behavior Therapy	Phase III

Study Type:	Interventional
Study Design:	Allocation: Randomized Primary Purpose: Treatment
Official Title:	Motivational Interviewing (MI) to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse

Resource links provided by NLM:

MedlinePlus related topics: Drug Abuse

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Drug use
Retention
HIV risk behaviors
Psychosocial functioning

Estimated Enrollment:	422
Study Start Date:	April 2001
Estimated Study Completion Date:	October 2002
Primary Completion Date:	October 2002 (Final data collection date for primary outcome measure)

Detailed Description:

Participants seeking treatment at the participating CTPs will be randomly assigned to either "standard" or "MET/MI" treatment, with a 1- and 3-month follow-up. Primary outcome measures will include (1) treatment retention (e.g., number of sessions/weeks completed, the rate of patients completing 3 or more subsequent sessions, and (2) substance use (e.g., urinalyses, days of opioid, cocaine, marijuana, alcohol use, rates of abstinence). Secondary outcomes will include motivation, psychosocial functioning, HIV risk behaviors, treatment utilization, and patient satisfaction. Process assessments will include measures of the working alliance as well as therapist adherence/competence ratings which will evaluate how effectively MET/MI was implemented. Participating CTPs will implement one of two independent protocols, depending on which is the best suited or feasible for the intake procedures at their clinic. Thus, following an invitation to participate, explanation of the study, and provision of informed consent, patients would complete a brief assessment battery followed by either:1) Random assignment to 3 individual sessions of standard treatment (treatment as usual) at the program versus 3 individual sessions of MET; or 2) Random assignment to 1 individual standard assessment/evaluation session.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Individuals will be eligible for the protocol who: a)Are seeking outpatient treatment for any substance use disorder. b)Are 18 years of age or older. c)Are willing to participate in the protocol (e.g., to be randomized to treatment, be contacted for follow-up assessment, to have their sessions audiotaped). d)Are able to understand and provide written informed consent.

Exclusion Criteria:

Individuals will be excluded who: a)Are not sufficiently medically or psychiatrically stable to participate in outpatient treatment. b)Are seeking detoxification only, methadone maintenance, or residential inpatient treatment.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00032994

Locations

United States, New York
Lower Eastside Service Center (LESC)
New York, New York, United States, 10007
United States, Oregon
Willamette Family Treatment Services
Eugene, Oregon, United States, 97402
Changepoint - Cedar Hills Blvd
Portland, Oregon, United States, 97292
ADAPT
Roseburg, Oregon, United States, 97470
United States, Virginia
Chesterfield County CSB- Substance Abuse Services
Chesterfield, Virginia, United States, 23832

Sponsors and Collaborators

Yale University

Investigators

Principal Investigator:

Kathleen Carroll, Ph.D.

VA Connecticut Healthcare System

More Information

Additional Information:

Data Elements This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Kathleen Carroll, Ph.D., Yale University School of Medicine
ClinicalTrials.gov Identifier:	NCT00032994 History of Changes
Obsolete Identifiers:	NCT00015730
Other Study ID Numbers:	NIDA-CTN-0005-1
Study First Received:	April 5, 2002
Last Updated:	April 13, 2010
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Substance-Related Disorders
Mental Disorders

ClinicalTrials.gov processed this record on February 12, 2012